CVS Trading Well Below Wall Street Targets After Month’s Softening Creates Opening

CVS Health's shares are trading below $94, significantly lower than the average analyst price target of $116.28 and nearly half the model's one-year target of $141.05. Management has raised its adjusted EPS guidance for 2026 to a range of $7.90 to $8.10, while Q2 earnings surpassed expectations by 38%. The stock has risen 18.4% year to date and 27.8% over the trailing year, outperforming the S&P 500's 11.2% gain.

However, the stock faces uncertainties related to Aetna's margin recovery, Pharmacy Benefit Manager (PBM) re-regulation, and drug pricing rules. With a forward P/E of 11x and a base-case one-year target of $141.05, the stock appears more attractive than Wall Street's current valuation. The recommendation is to buy shares, with a 49.6% upside potential, but the outcome depends on the durability of Aetna's margin recovery and the impact of PBM and drug pricing challenges.